Nivolumab Plus Ipilimumab for Advanced Melanoma: 5-Year Survival Rates and Side Effects

Research-informed explainer — last updated April 12, 2026

At 5 years, more than half of patients with advanced melanoma who received nivolumab plus ipilimumab in the CheckMate 067 trial were still alive — a figure that would have been unimaginable a decade ago, when the median survival for metastatic melanoma was measured in months. The combination does, however, carry a substantially higher rate of serious immune-related side effects than either drug alone, and understanding that tradeoff is essential before agreeing to treatment.

The long-term survival data comes from researchers at major cancer centers. Jedd Wolchok, Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, is the lead or senior author on the foundational CheckMate 067 trial (8,056 citations), the 2013 proof-of-concept combination trial (4,207 citations), and the 5-year survival analysis published in 2019 (3,646 citations) — the most comprehensive dataset on long-term outcomes with dual checkpoint blockade in melanoma. Jeffrey Sosman, Professor Emeritus at Northwestern and Director of the Melanoma Program at Lurie Cancer Center, contributed to the CheckMate 067 overall survival analysis (5,339 citations) and published the first systematic case series of fulminant myocarditis — a rare but potentially fatal immune-related adverse event — from combination checkpoint blockade (2,222 citations). Elizabeth Buchbinder, Assistant Professor of Medicine at Harvard Medical School, clarified the distinct biology of CTLA-4 and PD-1 pathways (2,248 citations) and led the first published neoantigen vaccine trial in melanoma (2,838 citations). Michael Davies at MD Anderson Cancer Center provides context on BRAF-targeted therapy, the alternative for the roughly 40–50% of melanoma patients whose tumors harbor the BRAF V600E mutation.

How the two drugs work — and why the combination is more powerful

Nivolumab and ipilimumab each block a different "checkpoint" — a brake that tumors use to suppress immune attack.

Ipilimumab (Yervoy) blocks CTLA-4, a checkpoint that controls how aggressively T cells proliferate after they first encounter a target. Blocking CTLA-4 effectively lowers the threshold for immune activation, generating a larger pool of tumor-fighting T cells. It works early in the immune response, in lymph nodes.

Nivolumab (Opdivo) blocks PD-1, a checkpoint that shuts down T cells that have already reached the tumor site. Many tumors display PD-L1, which binds PD-1 and neutralizes infiltrating T cells. Blocking PD-1 allows those T cells to keep fighting.

As Elizabeth Buchbinder's research clarifies, these two pathways operate at distinct stages of the immune response. Blocking both simultaneously generates broader and deeper immune activation than either drug alone — which explains both the improved efficacy and the higher toxicity.

What the 5-year survival data shows

The CheckMate 067 trial enrolled 945 previously untreated patients with advanced melanoma and randomly assigned them to nivolumab plus ipilimumab, nivolumab alone, or ipilimumab alone.

5-year overall survival rates (CheckMate 067, 2019 NEJM publication):

The combination arm also produced a median progression-free survival of 11.5 months, compared with 6.9 months for nivolumab alone and 2.9 months for ipilimumab alone.

Importantly, among patients whose tumors were PD-L1-negative, the combination was clearly superior to nivolumab alone: 5-year overall survival of 49% versus 39%. For PD-L1-positive patients, the advantage of combination over nivolumab alone was smaller and less consistent — meaning PD-L1 status helps predict who gains the most from the added toxicity of dual blockade.

The serious side effect question: what combination immunotherapy actually does to the body

The combination regimen carries a high rate of immune-related adverse events. In CheckMate 067, 59% of patients receiving the combination experienced grade 3–4 (severe) immune-related adverse events, compared with 21% for nivolumab alone and 28% for ipilimumab alone.

Common immune-related adverse events include:

• Colitis — severe diarrhea, sometimes requiring hospitalization and IV steroids
• Hepatitis — liver inflammation detected on blood tests, occasionally severe enough to require corticosteroids
• Endocrinopathies — hypothyroidism, hypophysitis (pituitary inflammation), adrenal insufficiency; most require long-term hormone replacement
• Skin toxicity — rash, vitiligo (which, interestingly, correlates with better tumor response)
• Pneumonitis — lung inflammation; presents as new shortness of breath or cough

The rare cardiac risk: Jeffrey Sosman's 2016 NEJM case series documented fatal fulminant myocarditis in two patients treated with nivolumab plus ipilimumab. Pharmacovigilance data subsequently showed myocarditis occurring in approximately 0.27% of patients on combination therapy. Though rare, the condition is disproportionately fatal when it occurs. Any new chest pain, shortness of breath, or irregular heartbeat during immunotherapy requires immediate medical evaluation.

Most immune-related adverse events are managed by pausing the drug and using corticosteroids. Some patients require permanent discontinuation of one or both drugs. Endocrine deficiencies typically require lifelong hormone replacement.

BRAF status: when targeted therapy is an alternative

Michael Davies at MD Anderson has studied dabrafenib plus trametinib extensively in BRAF V600E-mutant melanoma. Approximately 40–50% of melanomas carry a BRAF mutation, and for these patients, oral targeted therapy produces rapid, high-response-rate remissions — though durable long-term control has historically been shorter than with immunotherapy.

The practical question for patients with BRAF-mutant melanoma is which to start first. Current data does not clearly favor one sequence over the other, and clinical decisions depend on disease tempo (how fast the cancer is growing), tumor burden, BRAF status, PD-L1 expression, and patient fitness. This is an active area of investigation, and clinical trial enrollment should be considered.

Duration of response: does it last?

One of the most striking features of dual checkpoint blockade is the durability of responses. In CheckMate 067, patients who achieved a complete response had ongoing responses at 5 years in the majority of cases. Even partial responders showed sustained disease control over time. This durability distinguishes immunotherapy from most cytotoxic chemotherapy, where responses rarely persist after treatment ends.

Questions to ask your doctor

• What is my BRAF status, and does that change whether combination immunotherapy or targeted therapy is the better first choice?
• What is my tumor's PD-L1 expression level, and how does that affect whether I need the combination versus nivolumab alone?
• What is the monitoring plan for immune-related adverse events, and what symptoms should prompt an immediate call?
• If I develop serious side effects, how likely am I to be able to restart treatment?
• Am I eligible for any clinical trials comparing immunotherapy sequences or combinations with BRAF-targeted therapy?

The bottom line

Nivolumab plus ipilimumab represents a genuine step forward for advanced melanoma, with 5-year overall survival exceeding 50% in the CheckMate 067 trial — a result unachievable with prior therapies. The tradeoff is a high rate of serious immune-related side effects, including rare fatal events. Patients with BRAF-mutant melanoma have a meaningful alternative in targeted therapy and should discuss sequencing with their oncologist before committing to either approach.